Cell Lines

GenVec's established and proven ORF6 and M2A cell lines productively generate all of our proprietary adenovectors. Our cell lines perform excellently in serum-free, animal protein-free suspension culture and efficiently complement for the growth of even the most complex human-origin and nonhuman-origin adenovector constructs. These include vectors bearing the genes for multiple antigens, vectors bearing targeted expression cassettes, and vectors containing inserts that encode for proteins which interfere with the host cell metabolism and therefore pose challenges for scale-up and manufacture.  Our cell lines repeatedly and reliably produce high-concentration, stable adenovector lots that meet the rigorous GMP standards of our corporate and governmental collaborators as well as regulatory agencies.  

Highlights

  • GMP Master Cell Banks have been established for both the ORF6 and M2A cell lines
    • Thoroughly tested for safety, genetic and molecular characteristics, and stability
    • Characterization data have been submitted to the U.S. Food and Drug Administration in Biological Master File
    • Meet CMC requirements for worldwide production of biologicals
  • Applicable to a wide variety of vectors expressing target antigens and therapeutic genes
  • "Bioprocess-friendly" for high-yield bioreactor production in animal protein-free suspension culture
  • Utilized for GMP production of clinical trial materials in numerous programs, worldwide

ORF6 Cell Line

  • Therapeutics and vaccines manufactured using this cell line have been tested in over 3,000 clinical trial subjects
  • Complements for multiply-deleted adenovector production, generating Replication Competent Adenovirus (RCA)-free vector lots

M2A Cell Line

  • Designed to ensure the genetically stable, efficient, high-yield production of vectors bearing genes that interfere with host cell metabolism
  • The U.S. Department of Agriculture has accepted M2A cell products for use in vaccine production